BioSpace News Archive

Global Blood Therapeutics, Inc. announced that it will participate in virtual fireside chats at the following investor conferences.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), today announced that the first patient has been dosed in a China specific pivotal trial evaluating CBP-201 in adults with moderate-to-severe atopic dermatitis.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference.

Celsion Corporation (NASDAQ: CLSN), today announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 when immunizing BALB/c mice with the Company’s next-generation PLACCINE DNA vaccine platform.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following investor conferences.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it will present a company overview and business update at two upcoming investor conferences.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines’ Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines’ President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract award from the U.S. Department of Defense (DoD) to ensure reliable domestic production of pipette tips, which are used within research and diagnostic labs to dispense precise amounts of liquid

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the following upcoming conferences.